Hernádfői, M.; Szabados, M.; Brückner, E.; Varga, Á.; Hauser, P.; Ottóffy, G.; Vojcek, Á.; Csanádi, K.; Kertész, G.; Jakab, Z.;
et al. Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network. J. Clin. Med. 2025, 14, 6641.
https://doi.org/10.3390/jcm14186641
AMA Style
Hernádfői M, Szabados M, Brückner E, Varga Á, Hauser P, Ottóffy G, Vojcek Á, Csanádi K, Kertész G, Jakab Z,
et al. Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network. Journal of Clinical Medicine. 2025; 14(18):6641.
https://doi.org/10.3390/jcm14186641
Chicago/Turabian Style
Hernádfői, Márk, Márton Szabados, Edit Brückner, Ágnes Varga, Péter Hauser, Gábor Ottóffy, Ágnes Vojcek, Krisztina Csanádi, Gabriella Kertész, Zsuzsanna Jakab,
and et al. 2025. "Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network" Journal of Clinical Medicine 14, no. 18: 6641.
https://doi.org/10.3390/jcm14186641
APA Style
Hernádfői, M., Szabados, M., Brückner, E., Varga, Á., Hauser, P., Ottóffy, G., Vojcek, Á., Csanádi, K., Kertész, G., Jakab, Z., Agócs, G., & Garami, M.
(2025). Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network. Journal of Clinical Medicine, 14(18), 6641.
https://doi.org/10.3390/jcm14186641
